ReviewFrontiers in immunology2026
Autoimmune gastritis: a comprehensive review of pathophysiology, risk stratification, and management.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mechanisms and Biomarkers Driving the Transition From Chronic Atrophic Gastritis to Gastric Cancer.Clinical Medicine Insights. Oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune gastritis (AIG) is a chronic, organ-specific autoimmune disease characterized by the immune-mediated destruction of gastric parietal cells, leading to impaired acid secretion, vitamin B12 deficiency, and an increased risk of gastric malignancies. The diagnosis of AIG relies on endoscopic findings combined with serological markers and histopathological confirmation. This review synthesizes current knowledge on the pathophysiology, diagnosis, and management of AIG, with a special focus on familial aggregation, polyglandular autoimmunity, and emerging therapeutic strategies. We discuss the diagnostic challenges posed by serological variability, the complex interplay with Helicobacter pylori infection, and the diagnostic pitfalls of macrocytic anemia. Furthermore, we explore precision risk stratification models for gastric neuroendocrine tumors (gNETs) and gastric adenocarcinoma, emphasizing the roles of endoscopic surveillance and molecular biomarkers. Finally, we review emerging therapeutic options, including novel immunomodulators and microbiome-targeted interventions. This review provides a comprehensive framework for clinicians to navigate the complexities of AIG, from early diagnosis to long-term management, with the goal of improving patient outcomes and mitigating the risk of malignant transformation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.